ArticleBlood cancer journal2024
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- A practical approach to risk stratification of incidental T-cell clonality.Blood advances · 2026Review
- Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026Article
- TCRVβ-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.Blood advances · 2026Article
- Interpretable spatial multi-omics data integration and dimensionality reduction with SpaMV.Nature communications · 2026Article
- TCRbeta1/TCRbeta2 (TRBC1/TRBC2) antibody pair for determining T-cell monotypia as a surrogate for clonality in formalin-fixed paraffin-embedded material.Journal of clinical pathology · 2026Article
- Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood: A Case Series.Pediatric blood & cancer · 2026Article
- The Atypical and Suspicious for Malignancy Categories of the WHO Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Review of their Diagnostic Utility, Limitations, and Clinical Impact.Diagnostic cytopathology · 2026Review
- Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cells.Blood cancer journal · 2026Article
- Review
- Restricted Expression of the Constant Region 1 of T-Cell Receptor β by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value.European journal of haematology · 2026Article
- SpatialDG: a novel spatial domain identification method for spatially resolved transcriptomics data based on dual-graph neural network.Briefings in bioinformatics · 2026Article
- TCRγ constant usage tunes human γδ T cell antigen sensitivity, thymic programming, and peripheral function.Science immunology · 2026Article
- Article
- Immunohistochemical evaluation of T cell receptor and T cell receptor beta constant 1 expression distinguishes benign and neoplastic immature T-cell populations and reveals discrete TRBC1/TCR phenotypes.Journal of hematopathology · 2025Article
- TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T-Cell Lymphoma.EJHaem · 2025Article
- TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.Nature cancer · 2025Article
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Flow Cytometric Assessment of TRBC1 Expression for the Diagnosis of T-Cell Lymphoma: Clinical Utility and Pitfalls Related to T-Cell Clones of Uncertain Significance.International journal of laboratory hematology · 2025Article
- Interpretable spatial multi-omics data integration and dimension reduction with SpaMV.Research square · 2025Article
- Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 4 countries.
Funding
Abstract
The diagnosis of leukemic T-cell malignancies is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. Recently developed therapeutic antibodies specific for the mutually exclusive T-cell receptor constant β chain (TRBC)1 and TRBC2 isoforms provide a unique opportunity to assess for TRBC-restriction as a surrogate of clonality in the flow cytometric analysis of T-cell neoplasms. To demonstrate the diagnostic utility of this approach, we studied 164 clinical specimens with (60) or without (104) T-cell neoplasia, in addition to 39 blood samples from healthy donors. Dual TRBC1 and TRBC2 expression was studied within a comprehensive T-cell panel, in a fashion similar to the routine evaluation of kappa and lambda immunoglobulin light chains for the detection of clonal B-cells. Polytypic TRBC expression was demonstrated on total, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.